Elwha LLC

Tokitae LLC

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

The Invention Science Fund I LLC

Searete LLC

Gearbox LLC

Tokitac LLC

Philip Andrew Eckhoff

Lowell L Wood, Jr

Roderick A Hyde

Jordin T Kare

Muriel Y Ishikawa

Clarence T Tegreene

Nathan P Myhrvold

Victoria Y H Wood

William Henry Gates, Iii

David Bazeley Tuckerman

Robert Samuel Langer

Charles Whitmer

Alistair K Chan

Eric Leuthardt

Robert C Petroski

Jesse R Cheatham, Iii

Carlo Giovanni Traverso

Andrew Bellinger

Shiyi Zhang

Dean Liang Glettig

Elizabeth A Sweeney

Nels R Peterson

Angela DiCiccio

Stacy Mo

Peter L Hagelstein

Tyler Grant

Mousa Jafari

Michael Schnall-Levin

Edward K Y Jung

Tony S Pan

Dennis James Rivet, Ii

Erez Lieberman

Michael Baym

Shieng Liu

Lawrence Morgan Fowler

Bran Ferren

Thomas A Weaver

Geoffrey Frank Deane

Mahalaxmi Gita Bangera

John Latham

Fong-Li Chou

W Daniel Hillis

William David Duncan

Steven Nabil Bathiche

Kenneth Paul Hinckley

Anoop Gupta

Craig J Mundie

Matthew Graham Dyor

Paul Henry Dietz

Andreas Georg Nowatzyk

Danny Allen Reed

Fridrik Larusson

Max Nathan Mankin

David J Yager

Erez Lieberman Aiden

Jennifer Ezu Hu

Peter K Maier-Laxhuber

Kevin Michael Esvelt

Ralf W Schmidt

Reiner M Wörz

Wayne R Kindsvogel

Robert S Langer, Jr

Maurizio Vecchione

Daniel Jay MacDonald

Karima R Nigmatulina

Krishnan Natarajan

Brett M Bethke

Christopher Somogyi

Fong Li Chou

Dario G Amodei

Ankur Moitra

Lily Yvonne Kim

William Michael Kaminsky

Kyle B Gustafson

Anna Bershteyn

Xiaoyan Robert Bao

Jeremiah James Zartman

Kenneth G Caldeira

Ana Jaklenec

Brian L Pal

David Keith Piech

Boris Nikolic

Xian Xu

Orin Levine

Jiaqi Lin

William Gates

John Boomgard

Erez L Aiden

Edward KY Jung

Jesse R Iii Cheatham

In some embodiments, an affixed group of pharmaceutical vials with frangible connectors includes: a plurality of pharmaceutical vials arranged as a group of pharmaceutical vials, each of the plurality of pharmaceutical vials shaped and positioned to minimize a total volume of the group of pharmaceutical vials, each of the pharmaceutical vials including at least one external side with a surface configured to reversibly mate with a corresponding external side and a surface of an adjacent pharmaceutical vial; and a plurality of frangible connectors, wherein at least one frangible connector is affixed to the surface of at least two of the plurality of pharmaceutical vials within the group of pharmaceutical vials, and at least one frangible connector is affixed to each of the plurality of pharmaceutical vials.

Affixed groups of pharmaceutical vials including frangible connectors

Portage storage containers including controlled evaporative cooling systems are described herein. In some embodiments, a portable container including an integral controlled evaporative cooling system includes: a storage region, an evaporative region adjacent to the storage region, a desiccant region adjacent to the outside of the container, and an insulation region positioned between the evaporative region and the desiccant region. A vapor conduit with an attached vapor control unit has a first end within the evaporative region and a second end within the desiccant region. In some embodiments, the controlled evaporative cooling systems are positioned in a radial configuration within the portable container.

Temperature-controlled portable cooling units

Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Residence structures and related methods

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

Enteric elastomers and related methods are generally provided. In some embodiments, the enteric elastomer is a polymer composite. Certain embodiments comprise a polymer composite in which hydrogen bonds within two carboxyl group-containing polymers cross-link the polymer networks into an elastic and pH-responsive polymer composite. Advantageously, this polymer composite has the capacity of being stable and elastic in an acidic environment such as that of the stomach but can be dissolved in a neutral pH environment such as that of the small and large intestines. In some embodiments, the polymer composites described herein comprise a mixture of two or more polymers with carboxyl functionality such that the two or more polymers form hydrogen bonds. In certain embodiments, the polymer composite has both enteric and elastic properties.

Enteric elastomers

Residence devices as well as their related methods of manufacture and use are generally provided. In some embodiments, a residence device includes a plurality of self-assembling structures that assemble in vivo to form an aggregate structure. Each structure of the plurality of structures includes a first side and a first attachment point that attaches to a second attachment point on another structure of the plurality of structures. The aggregate structure may be sized and shaped to maintain an in vivo position relative to an internal orifice of a subject. The attachment between the first and second attachment points may degrade after a period of time.

Self-assembled residence devices and related methods

Certain embodiments involve administering a residence structure to a subject (e.g., a patient) in a constrained configuration, then unconstraining the structure such that it is retained at a location internally of the subject for a period of time. The structure includes a loadable component that can carry an active substance for release internally of the subject.

Certain embodiments involve gastric residence structures which can be administered to a subject (e.g., a patient) in a configuration constrained by a retaining element, and configured to mediate a change in shape when unconstrained by the retaining element to assume a configuration in the stomach in which is retained and unable to pass through the gastric pyloric orifice of the subject under gastrointestinal physiological conditions. The residence structures can be loaded with an agent for release in the stomach.

Described are gastric residence structures that include an active substance. The gastric residence structures may include one or more arms that include a loadable polymeric component, an elastic polymeric component, and a separate linker component. The linker may connect the one or more arms with the elastic polymeric component. The gastric residence structures may be configured to be folded and physically constrained during administration and may be configured to assume an open retention shape upon removal of a constraint. The change between the folded shape and the open retention shape may be mediated by the elastic polymeric component that undergoes elastic deformation when the residence structure is in the folded shape and recoils when the gastric residence structure assumes the open retention shape.

Described are methods of making a gastric residence structure including an active substance. The methods may include forming one or more arms comprising a loadable polymeric component, wherein the loadable polymeric component includes one or more polymeric materials and at least one active substance. The methods may also include connecting the one or more arms to an elastic polymeric component using a separate linker component. The gastric residence structures may be configured to be folded and physically constrained during administration and may be configured to assume an open retention shape upon removal of a constraint. The change between the folded shape and the open retention shape may be mediated by the elastic polymeric component that undergoes elastic deformation when the residence structure is in the folded shape and recoils when the gastric residence structure assumes the open retention shape.

Growing community of inventors

Kirkland, WA, United States of America

Philip Andrew Eckhoff